El interés en corto de IMAC Holdings da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de IMAC Holdings. Los datos de interés en corto se actualizan cada dos semanas.

IMAC Holdings (OTC:BACK) Bolsa, Informe de interés en corto

IMAC Hldgs

IMAC Holdings Inc is engaged in providing services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. The Company has determined that it currently operates in a single segment, precision medicine in cancer treatment, located in a single geographic location, the United States.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

IMAC Holdings Inc

Backblaze Inc

Backstageplay Inc

News

STRT

STRATTEC SECURITY CORPORATION Joins Russell 2000 And Russell 3000 Indexes

Maxim Group analyst Jack Vander Aarde initiates coverage on Cloudastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>) with a Buy rating and announces Price Target of $6.

Price Target

Initiation

Analyst Ratings

CSAI

Maxim Group Initiates Coverage On Cloudastructure with Buy Rating, Announces Price Target of $6

Acquisition adds unique materials characterization technology for advanced nodes, advanced packaging and compound semiconductor applications
Transaction expected to add over $130 million to Onto Innovation's annual revenue, be immediately accretive to gross and operating margins, and increase non-GAAP EPS by over 10% in year one
Onto Innovation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) today announced that it has entered into a definitive agreement to acquire the materials analysis business of Semilab International for $475 million in cash and 706,215 shares of Onto Innovation common stock. Based on the closing price of Onto Innovation's common stock on June 27, 2025, the total transaction value is approximately $545 million.
The acquisition adds four complementary product lines providing inline wafer contamination monitoring and materials interface characterization. As the use of exotic materials in semiconductor manufacturing rapidly expands, demand for advanced materials analysis is growing significantly. This portfolio has grown at an approximately 20% compound annual growth rate since 2021 and is projected to generate approximately $130 million in annual revenue in 2025. Onto Innovation expects to further enhance the customer value proposition by integrating its Ai Diffract&#x2122; modeling engine and leveraging advanced dimensional metrology, helping speed yield learning for new devices in packaging, power semiconductors and potentially the advanced nodes.
This acquisition aligns with Onto Innovation's strategy to excel in high-growth, high-margin segments of the semiconductor value chain, particularly where device complexity is accelerating, such as the production of chips required for AI applications. It reflects the company's disciplined approach to capital allocation and commitment to long-term shareholder value. The transaction is expected to be immediately accretive to both gross and operating margins and to increase non-GAAP earnings per share by more than 10% in the first year following close, adding over $130 million to Onto Innovation's annual revenue. Onto Innovation expects a smooth integration, supported by strong cultural and technical alignment between the two organizations.
The transaction is expected to close in the second half of 2025 and is subject to U.S. and Hungarian regulatory approvals and customary closing conditions. Onto Innovation and Semilab have aligned on detailed transition services to ensure customer continuity and post-close support.

ONTO

Onto Innovation Agrees To Acquire Materials Analysis Business Of Semilab International For $475M In Cash And 706,215 Shares Of Onto Innovation Common Stock

Keybanc analyst Eric Gonzalez maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Overweight and lowers the price target from $340 to $325.

Keybanc Maintains Overweight on McDonald's, Lowers Price Target to $325

B of A Securities analyst Joanna Gajuk maintains Chemed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHE#NYSE">CHE</a>) with a Buy and lowers the price target from $708 to $650.

B of A Securities Maintains Buy on Chemed, Lowers Price Target to $650

TransDigm Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) today announced it has entered into a definitive agreement to acquire the Simmonds Precision Products, Inc. Business ("Simmonds" or "the Company") of Goodrich Corporation from RTX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) for approximately $765 million in cash, including certain tax benefits.&nbsp;
Simmonds, headquartered in Vergennes, Vermont, is a leading global designer and manufacturer of fuel &amp; proximity sensing and structural health monitoring solutions for the aerospace and defense end markets. The Company's products are highly engineered, proprietary components with significant aftermarket content and a strong presence across major aerospace and defense platforms. &nbsp;Approximately 40% of Simmonds' revenue is derived from the aftermarket and nearly all of its revenue is generated from proprietary products. Simmonds is expected to generate approximately $350 million in revenue for the calendar year ending December 31, 2025. The Company employs approximately 900 people.
The acquisition is subject to regulatory approvals in the United States and customary closing conditions. The acquisition is expected to be financed through existing cash on hand.
 &nbsp;

TransDigm To Acquire Simmonds Precision Products Business Of Goodrich From RTX For ~$765M In Cash, Including Certain Tax Benefits

Hewlett Packard Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) and Juniper Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>) reached an agreement with the U.S. Department of Justice (DOJ) on Saturday.
This settlement, subject to court approval, resolves the DOJ&#8217;s lawsuit that challenged HPE&#8217;s acquisition of Juniper and paves the way for the transaction to close.
The acquisition was initially announced in January 2024, where HPE agreed to acquire Juniper in an all-cash transaction for $40.00 per share, valuing Juniper at <a target="_blank" href="https://www.benzinga.com/markets/equities/24/01/36571415/its-official-hewlett-packard-enterprise-buys-juniper-networks-in-a-massive-14b-deal" rel="noreferrer noopener">approximately $14 billion</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45776761/jpmorgan-bullish-on-hewlett-packard-enterprises-future-cites-durable-non-ai-segments-capital-returns" rel="noreferrer noopener">JPMorgan Bullish On Hewlett Packard Enterprise&#8217;s Future, Cites &#8216;Durable&#8217; Non-AI Segments, Capital Returns</a>
The DOJ, in a statement on Saturday, <a target="_blank" href="https://www.justice.gov/opa/pr/justice-department-requires-divestitures-and-licensing-commitments-hpes-acquisition-juniper" rel="noreferrer noopener">said</a>, &#8220;Achieving a result otherwise unavailable through litigation, earlier today, the Justice Department advised the court it had reached a settlement with HPE and Juniper that allows their merger to continue.&#8221;
The agreement satisfies the Department of Justice&#8217;s concerns while maintaining the overall value of the transaction to HPE customers, partners, and shareholders.
As part of the settlement, HPE has <a target="_blank" href="https://www.businesswire.com/news/home/20250628599766/en/HPE-and-Juniper-Networks-Reach-Settlement-With-U.S.-Department-of-Justice" rel="noreferrer noopener">agreed</a> to divest its global Instant On campus and branch business. After closing, HPE will facilitate limited access to Juniper&#8217;s advanced Mist AIOps technology.
Upon closing the deal, HPE and Juniper&#8217;s combined resources are expected to drive faster innovation across networking silicon, systems, and software.
&#8220;This marks an exciting step forward in delivering on a critical customer need, a complete portfolio of modern, secure networking solutions to connect their organizations and provide essential foundations for hybrid cloud and AI,&#8221; said Juniper Networks CEO Rami Rahim. &#8220;We look forward to closing this transaction and turning our shared vision into reality for enterprise, service provider, and cloud customers.&#8221;
For the second quarter, the company reported adjusted earnings per share of 38 cents, beating the consensus estimate of 33 cents. Hewlett posted sales of $7.63 billion, beating the consensus estimate of $7.50 billion, representing a <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45776696/hewlett-packard-stock-is-trading-higher-wednesday-whats-going-on" rel="noreferrer noopener">6% year-over-year climb</a>.
Price Action: Both HPE and JNPR saw significant gains in premarket trading on Monday. As of the last check on Monday, HPE stock climbed 12.7% to $20.74, while JNPR stock rose 8.42% to $39.92. This surge in share prices follows the announcement of the DOJ settlement, which clears a major hurdle for HPE&#8217;s acquisition of Juniper.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46166236/palantir-accenture-partner-to-infuse-ai-into-federal-agency-workflows" target="_blank" rel="noreferrer noopener">Palantir, Accenture Partner To Infuse AI Into Federal Agency Workflows</a></li>
</ul>
Photo via Shutterstock

Large Cap

Movers

Tech

General

JNPR

Why Is Hewlett Packard Stock Soaring On Monday?

Offerings

KANZHUN LIMITED Announces Pricing Of 34,500,000 Class A Ordinary Share Offer At HK$66.00 Per Share

HII And C3 AI Partner To Expand Digital Technologies, Apply AI To Accelerate Shipbuilding Throughput At HII's Newport News Shipbuilding And Ingalls Shipbuilding Divisions

Media

CURI

Curiosity University Launches On Amazon Prime Video Channels in Sweden

Asset Sales

ROCK

Gibraltar Industries Board approves Plan To Sell Renewables Business

Management

GAIA

Gaia Appoints Kiersten Medvedich As CEO

Rumble Added To Russell 2000 And Russell 3000 Indexes

Cantor Fitzgerald analyst Jonathan Ruykhaver initiates coverage on SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Overweight rating and announces Price Target of $29.

SAIL

Cantor Fitzgerald Initiates Coverage On SailPoint with Overweight Rating, Announces Price Target of $29

Maxim Group analyst Anthony Vendetti initiates coverage on Laird Superfood (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LSF#AMEX">LSF</a>) with a Buy rating and announces Price Target of $12.

Maxim Group Initiates Coverage On Laird Superfood with Buy Rating, Announces Price Target of $12

At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone
Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>, HKEX: 9688))) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.
Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and who are non-HER2 positive. FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry (IHC) testing.
A Phase 3 study of bemarituzumab plus chemotherapy and nivolumab is also ongoing in patients with first-line gastric cancer, with data readout anticipated in H2 2025.

ZLAB

Zai Lab Says Phase 3 FORTITUDE-101 Clinical Trial Evaluating First-Line Bemarituzumab Plus Chemotherapy Meets Primary Endpoint Of Overall Survival At Pre-Specified Interim Analysis

JMP Securities analyst Andrew Boone maintains Grindr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) with a Market Outperform and raises the price target from $24 to $27.

GRND

JMP Securities Maintains Market Outperform on Grindr, Raises Price Target to $27

Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) reported quarterly losses of $(0.36) per share. This is a 14.29 percent increase over losses of $(0.42) per share from the same period last year.

Earnings

Regencell Bioscience H1 EPS $(0.36) Up From $(0.42) YoY

High-Trend International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>), a Nasdaq-listed global shipping and logistics company, proudly acknowledges the recent correspondence from President Donald J. Trump in response to a letter submitted by Mr. Brian B. Su, the Company's Independent Director and Chairman of the Compensation Committee. In his letter dated June 18, 2025, President Trump expressed appreciation for Mr. Su's views on restoring American strength on the world stage and reaffirmed his administration's commitment to revitalizing American leadership, defense readiness, and strategic dominance in global affairs.

HTCO

High-Trend International Acknowledges President Trump Letter To Board Chairman On Company Affairs

Contracts

BZAI

Blaize Holdings Announces Its AI Platform Will Be Deployed Across Intelligence Surveillance Endpoints; Total Value Of Contracted Purchase Order ~$56M

Press Releases

IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors

IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology

IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1)

IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies

Stocks Under $2 to Watch in February 2025: TRIB, MODD, PNPN.V, BACK – More Inside!

Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response

Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay

Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

Comments

IMAC Holdings

Interés en corto

IMAC Holdings (OTC:BACK) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL